Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

Posted on by

JAMA
February 15, 2022, Vol 327, No. 7, Pages 605-693
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period
Lindsey Wang; Pamela B. Davis, MD, PhD; David C. Kaelber, MD, PhD, MPH; et al.
free access has active quiz
JAMA. 2022;327(7):678-680. doi:10.1001/jama.2022.0210
This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.